-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TR-4 in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TR-4 in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TR-4 in Asthma Drug Details: TR-4 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceclazepide in Helicobacter pylori Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceclazepide in Helicobacter pylori Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceclazepide in Helicobacter pylori Infections Drug Details: Ceclazepide (TR-2A) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TR-4 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TR-4 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TR-4 in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Cancer Drug Details: PT-217 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details: PT-217 is...
-
Product Insights
Gastritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastritis - Drugs In Development, 2023’, provides an overview of the Gastritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drugs In Development, 2023’, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Helicobacter pylori Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Helicobacter pylori Infections - Drugs In Development, 2023’, provides an overview of the Helicobacter pylori Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Esophageal Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Diseases - Drugs In Development, 2023’, provides an overview of the Esophageal Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...